Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Renal Cell 23Neoplasms 14Neoplasm Metastasis 14Glioblastoma 14Prostatic Neoplasms 13Breast Neoplasms 11Brain Neoplasms 11Sarcoma 10Lymphoma, Non-Hodgkin 10Kidney Neoplasms 10Endometrial Neoplasms 10Melanoma 9Lymphoma, Mantle-Cell 9Gliosarcoma 8Multiple Myeloma 7Glioma 7Ovarian Neoplasms 6Carcinoma, Hepatocellular 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Oligodendroglioma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 4Rhabdomyosarcoma 4

Interventions

temsirolimus 2liposomal doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Resistant Solid Malignancies × temsirolimus × Clear all
NCT00703625 2017-03-07

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Washington University School of Medicine

Phase 1 Completed
26 enrolled

Resistant Solid Malignancies

NCT00703170 2013-05-24

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Washington University School of Medicine

Phase 1 Completed
28 enrolled

Resistant Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡